Tag: BCR-ABL1 inhibitors

Home / BCR-ABL1 inhibitors

Categories

Ponatinib with chemotherapy has received accelerated approval by the USFDA for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

March 2024: Ponatinib (Iclusig, Takeda Pharmaceuticals U.S.A., Inc.) has received fast approval from the Food and Drug Administration for use in combination with chemotherapy in adult patients who hav...
bcr-abl1-inhibitors

Scan the code